Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03812991 · ClinicalTrials.gov registry record · Phase 4
The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries
A Phase 4 study of Pelvic Ring Fractures, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT03812991 is a Phase 4 study of Pelvic Ring Fractures that has completed, run by University of Missouri-Columbia. The registered enrollment target is 21 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03812991, a Phase 4 study of Pelvic Ring Fractures, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Pelvic ring fractures in the geriatric population are a rising problem for surgeons in industrialized countries. Many of these low-energy fractures are treated nonoperatively; however, pain is a significant factor in recovery of these patients and often inhibits their ability to mobilize. Most of these fractures are lateral compression type 1 injuries which are defined as an impaction to the sacrum with varying amounts of anterior/pubic root/rami fractures. Many of these patients in the geriatric population suffer from osteoporosis and the injuries are often sustained from a low-energy mechanism like a fall. The tenet of treatment for all osteoporotic fractures is early mobilization. It is well known that extended periods of bed rest will lead to pneumonia, decubitus ulceration, deep venous thrombosis, and, in the case of the pelvis, not prevent subsequent deformity. Calcitonin is a polypeptide containing 32 amino acids, and it plays a role in the regulation of bone metabolism as a hormone that prevents bone resorption. Intranasal salmon calcitonin (ISC) has been demonstrated to decrease pain and improve the level of activity in patients with acute vertebral osteoporotic compression fractures when administered within the first 5 days of onset of pain/injury. It has also demonstrated an immediate post analgesic effect in osteoporotic distal radius fractures treated nonoperatively. The antihyperalgesic action of calcitonin appears to be mediated by serotonin receptors. The purpose of this study is to evaluate the analgesic effect of ISC on geriatric patients with pelvic ring injuries who are treated nonoperatively.
Conditions Studied
Interventions
- DRUG Miacalcin Calcitonin Salmon Nasal Spray
Study Locations (1)
Missouri
- University of Missouri Health System - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03812991
The ClinicalTrials.gov registry entry for NCT03812991 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pelvic Ring Fractures appearing as the primary indexed condition, and to 1 intervention - of which Miacalcin Calcitonin Salmon Nasal Spray is the first listed.
NCT03812991 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT03812991 about?
NCT03812991 is a clinical study titled "The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries". Pelvic ring fractures in the geriatric population are a rising problem for surgeons in industrialized countries. Many of these low-energy fractures are treated nonoperatively; however, pain is a significant factor in recovery of these patients and often inhibits their ability to mobilize. Most of th...
What is the current status of trial NCT03812991?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2019-07-01. Estimated completion is 2023-02-28.
What conditions does trial NCT03812991 study?
This clinical trial studies the following conditions: Pelvic Ring Fractures.
What interventions are being tested in trial NCT03812991?
The interventions under investigation include: Miacalcin Calcitonin Salmon Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT03812991?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03812991 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.